Related Experiment Video
Updated: Apr 28, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
Shifeng Pan1, Nathanael S Gray1, Wenqi Gao1
1Genomics Institute of the Novartis Research Foundation , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States.
Abstract:
A novel series of alkoxyimino derivatives as S1P1 agonists were discovered through de novo design using FTY720 as the chemical starting point. Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid (32, BAF312, Siponimod), which has recently completed phase 2 clinical trials in patients with relapsing-remitting multiple sclerosis.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Antifungal Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacogenomics: Identification of New Drug Targets

